Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
UCB revenue increased from €4.9 billion in 2019 to €5.3 billion in 2020, a (8.8%) increase.

Annual Revenue ()

UCB revenue was €5.35 b in FY, 2020 which is a (8.8%) year over year increase from the previous period.

FY, 2018FY, 2019FY, 2020
Revenue€4.63 b€4.91 b€5.35 b

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Geographic Segment

UCB revenue breakdown by business segment: 35.8% from Cimzia®, 28.9% from Vimpat®, 15.7% from Keppra®, 6.2% from Neupro®, 5.7% from Briviact® and 7.7% from Other

UCB revenue breakdown by geographic segment: 17.7% from International, 27.4% from Europe and 54.9% from U.S.

FY, 2018FY, 2020FY, 2019
Cimzia®€1.45 b€1.8 b€1.71 b
Vimpat®€1.1 b€1.45 b€1.32 b
Keppra®€790 m€788 m€770 m
Neupro®€321 m€311 m€319 m
Briviact®€142 m€288 m€221 m
Xyzal®€101 m€74 m€101 m
Zyrtec®€90 m€75 m€89 m
Other€323 m€237 m€250 m
FY, 2018FY, 2020FY, 2019
International€829 m€889 m€906 m
Europe€1.33 b€1.37 b€1.33 b
U.S.€2.16 b€2.76 b€2.55 b

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu